News and Announcements
OpenDNA Limited (ASX: OPN) Signs MoU with Progressive Android Handset Manufacturer & Supplier Future Mobile Technology
- Published June 28, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Leading artificial intelligence company OpenDNA Limited (ASX: OPN) is pleased to announce the signature of a binding Memorandum of Understanding (“MOU”) with progressive Android handset manufacturer and supplier Future Mobile Technology (“FMT”), following which the parties will pursue opportunities in connection with the utilisation by FMT of OpenDNA’s personalisation and artificial intelligence technology in relation to its mobile devices.
KEY TAKEAWAYS:
- Binding MOU signed with Future Mobile Technology (“FMT”), manufacturer and provider of the high-quality “Netsurfer” range of Android mobile devices to the European and African markets
- Jottr,OpenDNA’s personalized content App, will be available on Google’s Play Store and pre-loaded on Netsurfer handsets and will host over 2,000 sources of rich content streams
- Through this pioneering development,OpenDNA-enriched Netsurfer Devices will “learn” and tailor news, entertainment, sports, technology, and lifestyle content to each individual user
- The strongly-growing Netsurfer brand provides a potentially lucrative opportunity under the MOU forOpenDNAto share in revenue derived by FMT from its user base
- OpenDNA’s innovative machine learning-powered personalization technology opens the way for Android device manufacturers to tailor services and content across Google’s rich content ecosystem, paving the way for the “Internet of Me”
In relation to the signing of the MOU, OpenDNA Managing Director and CEO Jay Shah said:
“Netsurfer products are beautifully designed and tailored to their customer base and we are excited about the opportunity to leverage our technology to push the boundaries even further by offering each individual user a highly tailored, personalized content experience. Smart devices have become integral to our lives – especially when we personalize them exactly to our preferences – and we are excited about the new era which OpenDNA is helping to usher in, whereby your device will personalize itself to your interests simply by using it.”
Tracy Andersson, FMT’s CEO, said:
“We recognise that OpenDNA is pioneering the way for machine learning to assist makers of smart devices to tailor content experiences for their users. Our partnership with OpenDNA was a natural fit – we want our users to ‘love their Netsurfer’ and the content experience is a major part of making that a reality.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
